ArticleClinical case reports2026
Metastatic Clear Renal Cell Carcinoma in Bladder Following Radical Nephrectomy, Metastasectomy, and Targeted Therapy: A Rare Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder metastasis from renal cell carcinoma (RCC) is relatively uncommon and may occur synchronously or metachronously, potentially without clinical symptoms. Notably, cases of bladder metastasis in advanced RCC following targeted therapy were particularly rare. Here we present the case of a 50-year-old female patient who underwent radical left nephrectomy for a renal tumor. Postoperative pathology confirmed clear cell renal cell carcinoma (ccRCC). Following the development of contralateral adrenal and metacarpal metastases, our institution performed metastatic lesion resection, after which the patient received adjuvant sunitinib therapy. Follow-up PET/CT revealed additional cranial bone metastasis and a suspicious bladder wall lesion. Subsequent surgical interventions included resection of the cranial metastasis and bladder mass, with pathology confirming metastatic ccRCC. Postoperatively, the patient was treated with axitinib combined with toripalimab. Despite treatment, the disease progressed with new widespread skeletal metastases, though no bladder recurrence was observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.